News of a second complaint filed to Indian regulators sent the drugmaker’s shares tumbling yet again, this time to their lowest point in about six years. The new complaint was said focus on a large number of dubious transactions between a Sun distributor and a firm controlled by Sun helmsman Dilip Shangvhi’s brother-in-law.
